

Please type a plus sign (+) inside this box → +

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	Unassigned
				Filing Date	August 27, 2003
				First Named Inventor	Axel ULLRICH
				Group Art Unit	Unassigned
				Examiner Name	Unassigned
Sheet	1	of	1	Attorney Docket Number	224160

U.S. PATENT DOCUMENTS						
Examiner Initials	Doc. No.	U.S. Patent Document		Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
		Application or Patent Number	Kind Code			

FOREIGN PATENT DOCUMENTS								
Examiner Initials	Doc. No.	Foreign Patent Document			Name of Patentee or Applicant	Date of Publication	Translation	
		Office	Application or Patent Number	Kind Code			Yes	No**
SAS	AA		WO 92/13948			08/22/92	Abstract	
	AB		WO 97/13771			4/17/97		
	AC		WO 98/24432			6/11/98		
	AD		WO 98/50356			11/12/98		

OTHER - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Doc. No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.	Translation	
			Yes	No**
SAS	AE	BUCHDUNGER et al., "4,5-bis (4-flouroanilino)phthalimide: a selective inhibitor of the epidermal growth factor receptor signal transduction pathway with potent <i>in vivo</i> antitumor activity," <i>Clin. Cancer Res.</i> , 1 (8), 813-821 (1995)		
	AF	CALBIOCHEM® Signal Transduction Catalog & Technical Resource, p. 259 (1998)		
	AG	CIARDELLO et al., "Cooperative effects of 8-chloro-cyclic AMP and 528 anti-epidermal growth factor receptor monoclonal antibody on human cancer cells," <i>Clin. Cancer Res.</i> , 1 (2), 161-167 (1995)		
	AH	COLL-FRESNO et al., "Cytotoxic activity of a diphteria toxin/FGF6 mitotoxin on human tumour cell lines," <i>Oncogene</i> , 14 (2), 243-247 (1997)		
	AI	DINNEY et al., "Therapy of human transitional cell carcinoma of the bladder by oral administration of the epidermal growth factor receptor protein tyrosine kinase inhibitor 4,5-dianilinophthalimide," <i>Clin. Cancer Res.</i> , 3 (2), 161-168 (1997)		
	AJ	HAN et al., "Preferential inhibition of glioblastoma cell with wild-type epidermal growth factor receptors by a novel tyrosine kinase inhibitor ethyl-2,5-dihydroxycinnamate," <i>Oncol. Res.</i> , 9 (11-12), 581-587 (1997)		
	AK	Mohammadi et al., <i>Science</i> , 276 (5314), 955-960 (May 9, 1997)		Not include b
	AL	Neilson KM, Friesel R., "Ligand-independent activation of fibroblast growth factor receptors by point mutations in the extracellular, transmembrane, and kinase domains," <i>J Biol Chem.</i> , 1996 Oct 4;271(40):25049-57		
	AM	NORMANNO et al., "Growth inhibition of human colon carcinoma cells by combinations of anti-epidermal growth factor-related growth factor antisense oligonucleotides," <i>Clin. Cancer Res.</i> , 2 (3), 601-609 (1996)		
	AN	PARTANEN et al., "FGFR-4, a novel acidic growth factor receptor with a distinct expression pattern," <i>EMBO J.</i> , 10 (6), 1347-1354 (1991)		
	AO	RUBIN GRANDIS et al., "Inhibition of epidermal growth factor receptor gene expression and function decreases proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells," <i>Oncogene</i> , 15 (4), 409-416 (1997)		
	AP	SHOWALTER et al., "Small molecule inhibitors of the platelet-derived growth factor receptor, the fibroblast growth factor receptor, and Src family tyrosine kinases," <i>Pharmacol. Ther.</i> , 76 (1-3), 55-61 (1997)		
AQ	UEHARA, "Recent advances in development of antitumor tyrosine kinase inhibitors," <i>Gen To Kagaku</i> , 24 (11), 1536-1540 (1997)		Abstract	

Examiner Signature S. J. Schaler	Date Considered 14/9/06
---	-------------------------

- * A concise statement of relevance is being submitted in lieu of a translation. 37 CFR 1.98(a)(3).
- + An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).